Literature DB >> 3458256

Oral heparin results in the appearance of heparin fragments in the plasma of rats.

A K Larsen, D P Lund, R Langer, J Folkman.   

Abstract

We have previously shown that angiogenesis inhibition and tumor regression can be accomplished by combinations of heparin or heparin fragments with cortisone [Folkman, J., Langer, R., Linhardt, R. J., Haudenschild, C. & Taylor, S. (1983) Science 221, 719-725]. Oral heparin was also effective in combination with cortisone. We now show that a single oral dose of [35S]heparin or [3H]heparin (15,000 units/kg) results in continuous release of radioactive material into the bloodstream for at least 12 hr. This is associated with the presence of anti-factor Xa activity at a level of approximately equal to 0.1 unit/ml. The radioactive material is identified as oligo-, di-, and monosaccharides by its behavior in chromatographic systems, its possession of anti-factor Xa activity, and the effect of treatment with bacterial heparinase. The heparin fragments are extensively metabolized to fragments without anti-factor Xa activity that are readily subject to urinary excretion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3458256      PMCID: PMC323427          DOI: 10.1073/pnas.83.9.2964

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  AN INVESTIGATION OF ROUTES OF ADMINISTRATION OF HEPARIN OTHER THAN INJECTION.

Authors:  E WINDSOR; L FREEMAN
Journal:  Am J Med       Date:  1964-09       Impact factor: 4.965

Review 2.  Chemistry and pharmacology of heparin.

Authors:  J Ehrlich; S S Stivala
Journal:  J Pharm Sci       Date:  1973-04       Impact factor: 3.534

3.  Exogenous 35S-labeled heparin: organ distribution and metabolism.

Authors:  T Stau; J Metz; R Taugner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

4.  Studies on the heparin sulphamidase activity from rat spleen. Intracellular distribution and characterization of the enzyme.

Authors:  Y Friedman; C Arsenis
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

5.  Isolation and characterization of oligosaccharides obtained from heparin by the action of heparinase.

Authors:  A Linker; P Hovingh
Journal:  Biochemistry       Date:  1972-02-15       Impact factor: 3.162

6.  Intestinal absorption of heparin.

Authors:  T Y Koh
Journal:  Can J Biochem       Date:  1969-10

7.  Degradation of (35S) heparin by mammalian and bacterial sulphamidases.

Authors:  A G Lloyd; L J Fowler; G Embery; B A Law
Journal:  Biochem J       Date:  1968-12       Impact factor: 3.857

8.  Effects of acidity, cations and alcoholic fractionation on absorption of heparin from gastrointestinal tract.

Authors:  T K Sue; L B Jaques; E Yuen
Journal:  Can J Physiol Pharmacol       Date:  1976-08       Impact factor: 2.273

9.  Oral contraceptives, antithrombin- III activity, and postoperative deep-vein thrombosis.

Authors:  S Sagar; J D Stamatakis; D P Thomas; V V Kakkar
Journal:  Lancet       Date:  1976-03-06       Impact factor: 79.321

10.  Novel heparin degradation products. Isolation and characterization of novel disaccharides and oligosaccharides produced from heparin by bacterial degradation.

Authors:  C P Dietrich
Journal:  Biochem J       Date:  1968-07       Impact factor: 3.857

View more
  10 in total

1.  Effects of the oral administration of glycosaminoglycans on cellular abnormalities associated with idiopathic calcium oxalate nephrolithiasis.

Authors:  B Baggio; G Gambaro; G Marzaro; F Marchini; A Borsatti; G Crepaldi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Polysaccharides as antiviral agents: antiviral activity of carrageenan.

Authors:  M E González; B Alarcón; L Carrasco
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

3.  Evidence that platelet and tumour heparanases are similar enzymes.

Authors:  C Freeman; A M Browne; C R Parish
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

4.  Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations.

Authors:  M Dryjski; D E Schneider; P Mojaverian; B S Kuo; T D Bjornsson
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

Review 5.  Angiostatic steroids. Method of discovery and mechanism of action.

Authors:  J Folkman; D E Ingber
Journal:  Ann Surg       Date:  1987-09       Impact factor: 12.969

Review 6.  The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins.

Authors:  Nusrat A Motlekar; Bi-Botti C Youan
Journal:  J Control Release       Date:  2006-06-14       Impact factor: 9.776

7.  Excretion of low molecular weight heparin in human milk.

Authors:  C Richter; J Sitzmann; P Lang; H Weitzel; A Huch; R Huch
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

8.  Metabolic fate of milk glycosaminoglycans in breastfed and formula fed newborns.

Authors:  Francesca Maccari; Veronica Mantovani; Orazio Gabrielli; Antonio Carlucci; Lucia Zampini; Tiziana Galeazzi; Fabio Galeotti; Giovanni V Coppa; Nicola Volpi
Journal:  Glycoconj J       Date:  2016-02-13       Impact factor: 2.916

9.  Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury.

Authors:  E R Edelman; D H Adams; M J Karnovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

Review 10.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.